FLT3 and acute myeloid leukemia: Based on encouraging data from a phase I/II study of azacitidine + sorafenib in relapsed/refractory FLT3-mutated AML [40], this combination was then evaluated as frontline therapy for patients >60 years of age with FLT3-mutated AML [41].